Oridonin attenuates synaptic loss and cognitive deficits in an Aβ1-42-induced mouse model of Alzheimer's disease

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Wang, Sulei ^a   Yu, Linjie ^b   Yang, Hui ^a   Li, Chaosheng ^a   Hui, Zhen ^a   Xu, Yun ^a,b,c,d,e   Zhu, Xiaolei ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^c Jiangsu Stroke Research Collaborative Group   (China)

^d Jiangsu Province Stroke Center for Diagnosis and Therapy   (China)

^e MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ORIDONIN; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOPHYSIN; AMYLOID BETA PROTEIN; DLGH4 PROTEIN, MOUSE; GUANYLATE KINASE; KAURANE DERIVATIVE; MEMBRANE PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; CELL DENSITY; CELL LOSS; CELL STRUCTURE; COGNITIVE DEFECT; CONTROLLED STUDY; DENDRITIC SPINE; DRUG MECHANISM; EMBRYO; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; MALE; MITOCHONDRION; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC LOSS; SYNAPTOSOME; ANIMAL; C57BL MOUSE; COGNITION DISORDERS; DRUG EFFECTS; HUMAN; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DENDRITIC SPINES; DITERPENES, KAURANE; GUANYLATE KINASES; HIPPOCAMPUS; HUMANS; MALE; MEMBRANE PROTEINS; MICE, INBRED C57BL; MITOCHONDRIA; RECEPTOR, TRKB; SIGNAL TRANSDUCTION; SYNAPSES; SYNAPTOPHYSIN;

EID: 84961626189     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151397     Document Type: Article

References (54)

1. 2015 Alzheimer's disease facts and figures. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2015; 11(3):332-84. PMID: 25984581.
2. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nature neuroscience. 2012; 15(3):349-57. doi: 10.1038/nn.3028 PMID: 22286176.
3. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harbor perspectives in medicine. 2012; 2(5):a006270. doi: 10.1101/cshperspect.a006270 PMID: 22553493.
4. Bai B, Hales CM, Chen PC, Gozal Y, Dammer EB, Fritz JJ, et al. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(41):16562-7. doi: 10.1073/pnas.1310249110 PMID: 24023061.
5. Guerreiro R, Bras J, Hardy J. SnapShot: genetics of Alzheimer's disease. Cell. 2013; 155(4):968-e1. doi: 10.1016/j.cell.2013.10.037 PMID: 24209629.
6. Pozueta J, Lefort R, Shelanski ML. Synaptic changes in Alzheimer's disease and its models. Neuroscience. 2013; 251:51-65. doi: 10.1016/j.neuroscience.2012.05.050 PMID: 22687952.
7. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiology of aging. 2006; 27(10):1372-84. doi: 10.1016/j.neurobiolaging.2005.09.012 PMID: 16289476.
8. McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology. 2014; 76 Pt A:57-67. doi: 10.1016/j.neuropharm.2013.08.005 PMID: 23973293.
9. Wei L, Lv S, Huang Q, Wei J, Zhang S, Huang R, et al. Pratensein attenuates Abeta-induced cognitive deficits in rats: enhancement of synaptic plasticity and cholinergic function. Fitoterapia. 2015; 101:208-17. doi: 10.1016/j.fitote.2015.01.017 PMID: 25665942.
10. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature reviews Neuroscience. 2013; 14(6):401-16. doi: 10.1038/nrn3505 PMID: 23674053.
11. Francis BM, Kim J, Barakat ME, Fraenkl S, Yucel YH, Peng S, et al. Object recognition memory and BDNF expression are reduced in young TgCRND8 mice. Neurobiology of aging. 2012; 33(3):555-63. doi: 10.1016/j.neurobiolaging.2010.04.003 PMID: 20447730.
12. Ciaramella A, Salani F, Bizzoni F, Orfei MD, Langella R, Angelucci F, et al. The stimulation of dendritic cells by amyloid beta 1-42 reduces BDNF production in Alzheimer's disease patients. Brain, behavior, and immunity. 2013; 32:29-32. doi: 10.1016/j.bbi.2013.04.001 PMID: 23578995.
13. Leal G, Comprido D, Duarte CB. BDNF-induced local protein synthesis and synaptic plasticity. Neuropharmacology. 2014; 76 PtC:639-56. doi: 10.1016/j.neuropharm.2013.04.005 PMID: 23602987.
14. Kim BK, Shin MS, Kim CJ, Baek SB, Ko YC, Kim YP. Treadmill exercise improves short-term memory by enhancing neurogenesis in amyloid beta-induced Alzheimer disease rats. Journal of exercise rehabilitation. 2014; 10(1):2-8. doi: 10.12965/jer.140086 PMID: 24678498.
15. Liu X, Ye K, Weinshenker D. Norepinephrine Protects against Amyloid-beta Toxicity via Trk B. Journal of Alzheimer's disease: JAD. 2015; 44(1):251-60. doi: 10.3233/JAD-141062 PMID: 25208620.
16. Middei S, Houeland G, Cavallucci V, Ammassari-Teule M, D'Amelio M, Marie H. CREB is necessary for synaptic maintenance and learning-induced changes of the AMPA receptor GluA1 subunit. Hippocampus. 2013; 23(6):488-99. doi: 10.1002/hipo.22108 PMID: 23504989.
17. Rodriguez-Tornos FM, San Aniceto I, Cubelos B, Nieto M. Enrichment of conserved synaptic activity-responsive element in neuronal genes predicts a coordinated response of MEF2, CREB and SRF. PLoS ONE. 2013; 8(1):e53848. doi: 10.1371/journal.pone.0053848 PMID: 23382855.
18. Kim J, Kwon JT, Kim HS, Han JH. CREB and neuronal selection for memory trace. Frontiers in neural circuits. 2013; 7:44. doi: 10.3389/fncir.2013.00044 PMID: 23519079.
19. Wang S, Yang H, Yu L, Jin J, Qian L, Zhao H, et al. Oridonin attenuates Abeta1-42-induced neuroinflammation and inhibits NF-kappaB pathway. PLoS ONE. 2014; 9(8):e104745. doi: 10.1371/journal.pone.0104745 PMID: 25121593.
20. Zhu X, Ye L, Ge H, Chen L, Jiang N, Qian L, et al. Hopeahainol A attenuates memory deficits by targeting beta-amyloid in APP/PS1 transgenic mice. Aging cell. 2013; 12(1):85-92. doi: 10.1111/acel.12022 PMID: 23107435.
21. Zhao H, Wang SL, Qian L, Jin JL, Li H, Xu Y, et al. Diammonium glycyrrhizinate attenuates Abeta(1-42) -induced neuroinflammation and regulates MAPK and NF-kappaB pathways in vitro and in vivo. CNS neuroscience & therapeutics. 2013; 19(2):117-24. doi: 10.1111/cns.12043 PMID: 23279783.
22. Zhu X, Wang S, Yu L, Yang H, Tan R, Yin K, et al. TL-2 attenuates beta-amyloid induced neuronal apoptosis through the AKT/GSK-3beta/beta-catenin pathway. Int J Neuropsychopharmacol. 2014; 17(9):1511-9. doi: 10.1017/S1461145714000315 PMID: 24641999.
23. Yu L, Wang S, Chen X, Yang H, Li X, Xu Y, et al. Orientin alleviates cognitive deficits and oxidative stress in Abeta1-42-induced mouse model of Alzheimer's disease. Life sciences. 2015; 121:104-9. doi: 10.1016/j.lfs.2014.11.021 PMID: 25497709.
24. Chen YT, Zang XF, Pan J, Zhu XL, Chen F, Chen ZB, et al. Expression patterns of histone deacety-lases in experimental stroke and potential targets for neuroprotection. Clinical and experimental pharmacology & physiology. 2012; 39(9):751-8. doi: 10.1111/j.1440-1681.2012.05729.x PMID: 22651689.
25. Jin JL, Liou AK, Shi Y, Yin KL, Chen L, Li LL, et al. CART treatment improves memory and synaptic structure in APP/PS1 mice. Scientific reports. 2015; 5:10224. doi: 10.1038/srep10224 PMID: 25959573.
26. Palavicini JP, Wang H, Bianchi E, Xu S, Rao JS, Kang DE, et al. RanBP9 aggravates synaptic damage in the mouse brain and is inversely correlated to spinophilin levels in Alzheimer's brain synaptosomes. Cell death & disease. 2013; 4:e667. doi: 10.1038/cddis.2013.183 PMID: 23764848.
27. Shao CY, Mirra SS, Sait HB, Sacktor TC, Sigurdsson EM. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Abeta and tau pathology in transgenic mouse models of Alzheimer's disease. Acta neuropathologica. 2011; 122(3):285-92. doi: 10.1007/s00401-011-0843-x PMID: 21630115.
28. Zeng Y, Zhang J, Zhu Y, Shen H, Lu J, Pan X, et al. Tripchlorolide improves cognitive deficits by reducing amyloid beta and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease. Journal of neurochemistry. 2015; 133(1):38-52. doi: 10.1111/jnc.13056 PMID: 25661995.
29. Yuki D, Sugiura Y, Zaima N, Akatsu H, Takei S, Yao I, et al. DHA-PCand PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer's disease. Scientific reports. 2014; 4:7130. doi: 10.1038/srep07130 PMID: 25410733.
30. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(39):16877-82. doi: 10.1073/pnas.0908706106 PMID: 19805389.
31. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005; 47(2):191-9. doi: 10.1016/j.neuron.2005.06.030 PMID: 16039562.
32. Mo JA, Lim JH, Sul AR, Lee M, Youn YC, Kim HJ. Cerebrospinal fluid beta-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease - systematic review and meta-analysis. PLoS ONE. 2015; 10(2):e0116802. doi: 10.1371/journal.pone.0116802 PMID: 25710596.
33. Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. Journal of the neurological sciences. 1987;78(2):151-64. PMID: 3572454.
34. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiology of aging. 1995; 16(3):285-98; discussion 98-304. PMID: 7566338.
35. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr., et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 2001; 56(1):127-9. PMID: 11148253.
36. Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. The American journal of pathology. 1991; 138(1):235-46. PMID: 1899001.
37. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. Journal of neuropathology and experimental neurology. 1997; 56(8):933-44. PMID: 9258263.
38. Ferreira ST, Klein WL. The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiology of learning and memory. 2011; 96(4):529-43. doi: 10.1016/j.nlm.2011.08.003 PMID: 21914486.
39. Xu S, Liu G, Bao X, Wu J, Li S, Zheng B, et al. Rosiglitazone prevents amyloid-beta oligomer-induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number. Journal of Alzheimer's disease: JAD. 2014; 39(2):239-51. doi: 10.3233/JAD-130680 PMID: 24150104.
40. Kirkwood CM, Ciuchta J, Ikonomovic MD, Fish KN, Abrahamson EE, Murray PS, et al. Dendritic spine density, morphology, and fibrillar actin content surrounding amyloid-beta plaques in a mouse model of amyloid-beta deposition. Journal of neuropathology and experimental neurology. 2013; 72(8):791-800. doi: 10.1097/NEN.0b013e31829ecc89 PMID: 23860033.
41. Bittner T, Burgold S, Dorostkar MM, Fuhrmann M, Wegenast-Braun BM, Schmidt B, et al. Amyloid plaque formation precedes dendritic spine loss. Acta neuropathologica. 2012; 124(6):797-807. doi: 10.1007/s00401-012-1047-8 PMID: 22993126.
42. Price KA, Varghese M, Sowa A, Yuk F, Brautigam H, Ehrlich ME, et al. Altered synaptic structure in the hippocampus in a mouse model of Alzheimer's disease with soluble amyloid-beta oligomers and no plaque pathology. Molecular neurodegeneration. 2014; 9:41. doi: 10.1186/1750-1326-9-41 PMID: 25312309.
43. Wilcox KC, Marunde MR, Das A, Velasco PT, Kuhns BD, Marty MT, et al. Nanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer's-Associated Abeta Oligomers. PLoS ONE. 2015; 10(4):e0125263. doi: 10.1371/journal.pone.0125263 PMID: 25928376.
44. Sokolow S, Henkins KM, Bilousova T, Gonzalez B, Vinters HV, Miller CA, et al. Presynaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease. Journal of neurochemistry. 2015; 133(3):368-79. doi: 10.1111/jnc.12991 PMID: 25393609.
45. Evans GJ. The synaptosome as a model system for studying synaptic physiology. Cold Spring Harbor protocols. 2015; 2015(5):421-4. doi: 10.1101/pdb.top074450 PMID: 25934942.
46. Sokolow S, Henkins KM, Williams IA, Vinters HV, Schmid I, Cole GM, et al. Isolation of synaptic terminals from Alzheimer's disease cortex. Cytometry Part A: the journal of the International Society for Analytical Cytology. 2012; 81(3):248-54. doi: 10.1002/cyto.a.22009 PMID: 22213704.
47. Postupna NO, Keene CD, Latimer C, Sherfield EE, Van Gelder RD, Ojemann JG, et al. Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease. Laboratory investigation; ajournal of technical methods and pathology. 2014; 94(10):1161-72. doi: 10.1038/labinvest.2014.103 PMID: 25068655.
48. Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. Journal of neuropathology and experimental neurology. 2010; 69(2):155-67. doi: 10.1097/NEN.0b013e3181cb5af4 PMID: 20084018.
49. Bayrakdar ET, Armagan G, Uyanikgil Y, Kanit L, Koylu E, Yalcin A. Ex vivo protective effects of nicotinamide and 3-aminobenzamide on rat synaptosomes treated with Abeta(1-42). Cell biochemistry and function. 2014; 32(7):557-64. doi: 10.1002/cbf.3049 PMID: 25111857.
50. Chen K, Henry RA, Hughes SM, Connor B. Creating a neurogenic environment: the role of BDNF and FGF2. Molecular and cellular neurosciences. 2007; 36(1):108-20. doi: 10.1016/j.mcn.2007.06.004 PMID: 17656107.
51. Rivera C, Li H, Thomas-Crusells J, Lahtinen H, Viitanen T, Nanobashvili A, et al. BDNF-inducedTrkB activation down-regulates the K+-Cl- cotransporter KCC2 and impairs neuronal Cl- extrusion. The Journal of cell biology. 2002; 159(5):747-52. doi: 10.1083/jcb.200209011 PMID: 12473684.
52. Yamada K, Nabeshima T. Brain-derived neurotrophic factor/TrkB signaling in memory processes. Journal of pharmacological sciences. 2003; 91(4):267-70. PMID: 12719654.
53. Zhang F, Kang Z, Li W, Xiao Z, Zhou X. Roles of brain-derived neurotrophic factor/tropomyosin-related kinase B (BDNF/TrkB) signalling in Alzheimer's disease. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2012; 19(7):946-9. doi: 10.1016/j.jocn.2011.12.022 PMID: 22613489.
54. Yoshii A, Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Developmental neurobiology. 2010; 70(5):304-22. doi: 10.1002/dneu.20765 PMID: 20186705.